Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
PruritusAtopic Dermatitis
Interventions
DRUG

Asimadoline

kappa-opioid receptor agonist

DRUG

Placebo

placebo-matched control

Trial Locations (22)

14830

Corning Center for Clinical Research, Corning

19104

University of Pennsylvania, Department of Dermatology, Philadelphia

19140

Temple Itch Center, Philadelphia

27104

Wake Forest Baptist Health, Winston-Salem

27516

UNC Dermatology and Skin Cancer Center, Chapel Hill

29407

Medical Research South, Charleston

29420

National Allergy and Asthma Research, LLC, North Charleston

29621

Radiant Research, Inc., Anderson

32073

Park Avenue Dermatology, Orange Park

33162

Tory Sullivan, MD PA, North Miami Beach

33609

Olympian Clinical Research, Tampa

35244

Clinical Research Center of Alabama, Birmingham

46032

Forefront Dermatology, Carmel

61761

Sneeze, Wheeze and Itch Associates, LLC, Normal

64506

MediSearch Clinical Trials, Saint Joseph

75230

Dermatology Treatment and Research Center, PA, Dallas

78229

Sylvana Research Associates, San Antonio

83704

Northwest Clinical Trials, Boise

90027

Children's Hospital Los Angeles, Los Angeles

90036

Axis Clinical Research, Los Angeles

97239

Oregon Health and Science University, Portland

07044

The Dermatology Group, Verona

Sponsors
All Listed Sponsors
lead

Tioga Pharmaceuticals

INDUSTRY

NCT02475447 - Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis | Biotech Hunter | Biotech Hunter